Aplitibart for Metastatic Colorectal Cancer

No longer recruiting at 76 trial locations

Overseen By Clinical Trials

Age: 18+

Sex: Any

Trial Phase: Phase 1

Must not be taking: Liver toxicity agents, Anticancer agents

Disqualifiers: CNS metastases, Major surgery, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new treatment called aplitabart for individuals with tough-to-treat colorectal cancer. Researchers aim to assess its safety and tolerability both alone and in combination with other cancer drugs like FOLFIRI (a chemotherapy regimen) and bevacizumab (also known as Avastin, a targeted therapy). The trial includes various treatment groups to identify the best combination or dosing schedule. It suits those whose colorectal cancer did not respond to prior treatments but who have not yet tried FOLFIRI. Participants should manage daily activities independently and have a confirmed diagnosis of advanced cancer. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

Will I have to stop taking my current medications?

The trial requires that you stop taking any anti-cancer agents and certain other medications before starting the study treatment. If you are on medications that cause liver toxicity or have recently used chemotherapy or other specific treatments, you may need to stop those as well.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

A previous study found aplitabart alone to be safe, with patients tolerating it well and no major safety issues reported. When combined with FOLFIRI and bevacizumab, aplitabart remained generally safe, though patients experienced expected chemotherapy side effects, such as tiredness and nausea.

Early research on aplitabart with birinapant suggests it is manageable, though it can cause typical chemotherapy side effects. Real-world data shows that aplitabart with venetoclax is usually well-tolerated, but it can lead to low white blood cell counts.

Other studies found the combination of aplitabart with docetaxel and gemcitabine to be safe, with common side effects like tiredness. Lastly, when combined with venetoclax and azacitidine, aplitabart has been associated with manageable side effects such as constipation and nausea.

This trial is in its earliest phase, focusing on determining the treatment's safety at different doses. So far, no major safety concerns have emerged, but this phase aims to ensure it is safe for more people. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about Aplitabart for colorectal cancer because it offers a novel approach by potentially enhancing the effectiveness of existing chemotherapy drugs. Unlike standard treatments like FOLFIRI and bevacizumab, Aplitabart works in combination with these drugs and others, potentially boosting their cancer-fighting power. This combination strategy might offer a more robust attack on cancer cells, potentially leading to better outcomes for patients. Additionally, Aplitabart is being tested with various other compounds like Venetoclax and Azacitidine, aiming to discover the most effective synergistic combinations. By exploring these new combinations, researchers hope to improve treatment efficacy and expand options for patients with advanced colorectal cancer.

What evidence suggests that this trial's treatments could be effective for colorectal cancer?

Research has shown that aplitabart alone is promising and safe in early studies. In this trial, participants may receive aplitabart as a single agent or in combination with other treatments. One arm will test aplitabart combined with FOLFIRI and bevacizumab, aiming to enhance the effectiveness of these drugs, which have proven effective in treating colorectal cancer. Another arm will explore pairing aplitabart with Birinapant, targeting cancer cell survival and potentially offering a strong treatment option. Studies on venetoclax with aplitabart have suggested improved cancer treatment outcomes, as venetoclax can inhibit cancer cell growth; this combination will be tested in another arm. Additionally, combining aplitabart with docetaxel and gemcitabine has been safely tested in certain colorectal cancer cases and will be evaluated in this trial. Finally, using aplitabart with venetoclax and azacitidine has shown better overall results compared to azacitidine alone, and this combination will also be part of the study. ^{2 5 6 7 8}

Who Is on the Research Team?

Eric Humke, MD, PhD

Principal Investigator

IGM Biosciences

Are You a Good Fit for This Trial?

This trial is for adults with colorectal cancer that has returned or spread after treatment. Participants can have had prior treatments, must be able to perform light daily activities, and should not have been treated with irinotecan for their cancer.

Inclusion Criteria

Can you move around easily and do simple tasks like light housework or office work during the day?

Are you mobile and able to carry out light work throughout your day? (e.g. light house work or office work)

Has your colorectal cancer progressed within the last 6 months?

Exclusion Criteria

Have you ever received Irinotecan, (otherwise known as Camptosar and/or Onivyde) to treat your colorectal cancer?

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Phase 1a Treatment

Participants receive aplitabart as a single agent or in combination with other agents in a dose-escalation and expansion stage

6 months

Regular visits at pre-defined intervals

Phase 1b Treatment

Colorectal participants receive aplitabart in combination with FOLFIRI and bevacizumab in an open-label, randomized study

36 months

Regular visits at pre-defined intervals

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Azacitidine
• Bevacizumab
• Birinapant
• Docetaxel
• FOLFIRI
• Gemcitabine
• IGM-8444
• Venetoclax

Trial Overview

The study is examining the safety and effectiveness of aplitibart combined with FOLFIRI chemotherapy and bevacizumab in treating advanced colorectal cancer. It aims to find out if this new combination can help patients whose cancer has relapsed or spread.

How Is the Trial Designed?

Group I: Ph1b: FOLFIRI + Bevacizumab Experimental Treatment 2 Interventions

Standard of Care FOLFIRI + bevacizumab will be administered intravenously

Group II: Ph1b: Aplitabart + FOLFIRI + Bevacizumab Experimental Treatment 3 Interventions

Aplitabart will be administered intravenously in combination with FOLFIRI + bevacizumab

Group III: Ph1a: Aplitabart Single Agent Alternate Dosing Escalation Experimental Treatment 1 Intervention

Aplitabart will be administered intravenously as a single agent on an alternate dosing schedule.

Group IV: Ph1a: Aplitabart + Venetoclax Escalation and Expansion Experimental Treatment 2 Interventions

Aplitabart will be administered intravenously in combination with Venetoclax.

Group V: Ph1a: Aplitabart + Venetoclax + Azacitidine Escalation and Expansion Experimental Treatment 3 Interventions

Aplitabart will be administered intravenously in combination with Venetoclax and Azacitidine.

Group VI: Ph1a: Aplitabart + FOLFIRI ± bevacizumab Escalation and Expansion Experimental Treatment 3 Interventions

Aplitabart will be administered intravenously in combination with FOLFIRI± bevacizumab.

Group VII: Ph1a: Aplitabart + Docetaxel + Gemcitabine Escalation and Expansion Experimental Treatment 3 Interventions

Aplitabart will be administered intravenously in combination with Docetaxel and Gemcitabine.

Group VIII: Ph1a: Aplitabart + Birinapant Escalation and Expansion Experimental Treatment 2 Interventions

Aplitabart will be administered intravenously in combination with Birinapant which will also be administered intravenously.

Azacitidine is already approved in European Union, United States, Canada, Japan for the following indications:

Approved in European Union as Vidaza for:

• Acute myeloid leukemia
• Chronic myelomonocytic leukemia
• Myelodysplastic syndromes

Approved in United States as Vidaza for:

• Myelodysplastic syndromes
• Chronic myelomonocytic leukemia

Approved in Canada as Vidaza for:

• Myelodysplastic syndromes
• Acute myeloid leukemia

Approved in Japan as Vidaza for:

• Myelodysplastic syndromes
• Acute myeloid leukemia

Who Is Running the Clinical Trial?

Lead Sponsor

Trials

1

Recruited

270+

IGM Biosciences, Inc.

Lead Sponsor

Trials

10

Recruited

520+

Lead Sponsor

Trials

1

Recruited

270+

Published Research Related to This Trial

In a study of 94 patients aged 70 and older with advanced colorectal cancer, both CAPOX and CAPIRI treatments showed similar overall response rates (38% for CAPOX and 36% for CAPIRI), indicating comparable efficacy as first-line treatments.

CAPOX was better tolerated than CAPIRI, with fewer severe side effects such as diarrhea and neutropenia, suggesting it may be a safer option for elderly patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Rosati, G., Cordio, S., Bordonaro, R., et al.[2020]

Irinotecan has been shown to significantly prolong survival in patients with 5-FU-resistant colorectal cancer compared to best supportive care or 5-FU-based chemotherapy, based on Phase III studies.

Combining irinotecan with other treatments, such as raltitrexed or oral fluoropyrimidines, has shown promising results in terms of safety and efficacy, with response rates exceeding 30% and median survival benefits in various cancer types.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies. Armand, JP., Cunningham, D., van Cutsem, E., et al.[2019]

Irinotecan has been established as a standard treatment for advanced/metastatic colorectal cancer, showing survival benefits over best supportive care and 5-fluorouracil (5-FU) without negatively affecting patients' quality of life.

Combining irinotecan with oral capecitabine has shown promising results in terms of efficacy and safety, offering a more convenient treatment option compared to traditional infused 5-FU, and represents a potential new standard for first-line therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Optimizing the use of irinotecan in colorectal cancer. Cunningham, D., Maroun, J., Vanhoefer, U., et al.[2019]

The evolution of chemotherapy for colorectal cancer has shifted from the single-agent use of 5-fluorouracil (5-FU) to more effective combination regimens that include irinotecan, oxaliplatin, and targeted agents like bevacizumab, significantly improving patient survival rates.

Combination therapies utilizing 5-FU as a base have been shown to enhance treatment outcomes, highlighting the importance of integrating newer drugs into established regimens for better management of colorectal cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Current approaches to first-line treatment of advanced colorectal cancer. Goldberg, RM.[2019]

The combination of FOLFIRI and aflibercept was found to be active and tolerable in treating metastatic colorectal cancer (mCRC), with an objective response rate of 46.6% among 73 patients, indicating potential effectiveness in this patient population.

Despite its activity, the regimen did not surpass historical benchmarks for efficacy in chemotherapy-naive patients, with a 12-month progression-free survival rate of only 21.9% and a median overall survival of 20.9 months, suggesting that while it may help some patients, it may not be a significant improvement over existing treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. Pentheroudakis, G., Kotoula, V., Koliou, GA., et al.[2019]

Irinotecan has shown significant activity against advanced colorectal cancer when combined with traditional chemotherapy agents like fluorouracil, leading to clinical responses including complete remissions in patients.

The combination therapies have acceptable toxicity profiles, with neutropenia and delayed diarrhea being the most common side effects, indicating that irinotecan could be a safe option for treatment, although further large-scale phase III studies are needed to confirm its benefits.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

European experience with irinotecan plus fluorouracil/folinic acid or mitomycin. Khayat, D., Gil-Delgado, M., Antoine, EC., et al.[2018]

The modified FOLFIRI regimen, which includes irinotecan, 5-fluorouracil, and a low dose of leucovorin, demonstrated a 47.8% overall response rate in 44 patients with recurrent or metastatic colorectal cancer, indicating its efficacy as a first-line treatment.

The treatment was well-tolerated, with mild and manageable toxicities; only a few patients experienced severe side effects, such as Grade 3/4 leukopenia and diarrhea, suggesting a favorable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer. Lee, MA., Byun, JH., Shim, BY., et al.[2019]

A phase II study involving 43 patients with advanced gastrointestinal tumors showed that capecitabine combined with either irinotecan or oxaliplatin is effective in treating colorectal and other GI cancers, demonstrating significant clinical activity as both first-line and salvage therapy.

The combination therapies exhibited an excellent safety profile, with manageable grade 3/4 toxicities primarily limited to diarrhea, and no severe myelosuppression observed, indicating that these regimens are safe for patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers. Jordan, K., Kellner, O., Kegel, T., et al.[2019]

The combination of FOLFOXIRI and bevacizumab demonstrated a promising progression-free survival (PFS) rate of 74% at 10 months in patients with unresectable metastatic colorectal cancer, based on a phase 2 study involving 57 patients.

The treatment was found to be safe, with no unexpected adverse events reported, although common serious side effects included neutropenia and hypertension, indicating that while effective, careful monitoring for these side effects is necessary.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Masi, G., Loupakis, F., Salvatore, L., et al.[2022]

Citations

1.

clin.larvol.com

clin.larvol.com/trial-detail/NCT04553692

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in ...

This randomized trial will assess the additional benefit of 3 mg/kg of aplitabart with a primary endpoint of progression-free survival (PFS) and secondary ...

2.

withpower.com

withpower.com/trial/phase-1-chondrosarcoma-8-2020-e60f6

Aplitibart for Metastatic Colorectal Cancer

In a study of 94 patients aged 70 and older with advanced colorectal cancer, both CAPOX and CAPIRI treatments showed similar overall response rates (38% for ...

3.

delta.larvol.com

delta.larvol.com/Products/?ProductId=d4595b28-cfeb-4192-9b6d-e17adf6fbbb9

aplitabart (IGM-8444) / IGM Biosciences

IGM-8444-001: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers ...

4.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC11402684/

Targeting Death Receptor 5 (DR5) for the imaging and ...

Investigations have also demonstrated effectiveness in solid tumor colorectal cancer PDX models (Phillips et al., 2021). IGM-8444 (aplitabart).

5.

finance.yahoo.com

finance.yahoo.com/news/igm-biosciences-announces-second-quarter-201000539.html

IGM Biosciences Announces Second Quarter 2023 ...

This randomized trial will assess the additional benefit of 3 mg/kg of aplitabart with a primary endpoint of progression-free survival (PFS) and ...

6.

clinicaltrials.gov

clinicaltrials.gov/study/NCT04553692

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in ...

This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart as a ...

7.

clinicaltrials.gov

clinicaltrials.gov/study/NCT01188499

Dose Escalation, Combination Chemotherapy Safety Study ...

The purpose of this study is to determine the safety and maximum tolerated dose of birinapant (TL32711) as a 30 minute intravenous infusion ...

8.

cancer.gov

cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2020-12872

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in ...

This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart.